A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.

Trial Profile

A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Acronyms SUNRISE
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 27 Jul 2016 to 1 Dec 2017.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology. (n = 20)
    • 07 Feb 2014 New source identified and integrated, ClincialTrials.gov record (NCT02058901).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top